Other languages Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Market Closed - Nasdaq Other stock markets 02:00:00 22/05/2024 am IST			5-day change	1st Jan Change
4.088 ^USD	-2.67%		+2.71%	-25.68%

15/05	Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M	MT
30/04	Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	22/01
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	08/01
Top Midday Gainers	12/12
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	11/12
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	11/23/11
Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15
Marker Therapeutics Says Non-clinical Data Show MT-401 Inducing Anti-tumor Activity in Specific Setting	07/23/07
Marker Therapeutics Says Acute Myeloid Leukemia Treatment Candidate Granted Orphan Drug Designation in European Union	10/23/10
Marker Therapeutics, Inc. Announces Zedenoleucel, Its Multi-Tumor-Associated Antigen-Specific T Cell Product Candidate, Mt-401	10/23/10
Marker Therapeutics Says MT-401 Non-clinical Data Show Anti-Tumor Activity Against Acute Myeloid Leukemia	27/23/27
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells After Hypomethylating Agent Administration	26/23/26
Cell Ready, LLC completed the acquisition of Certain Cell Manufacturing Assets of Marker Therapeutics, Inc.	26/23/26
Marker Therapeutics Says First Patient Dosed in Phase 1 Trial of Lymphoma Treatment	12/23/12
Sector Update: Health Care Stocks Advancing Late Wednesday	01/23/01
Sector Update: Health Care Stocks Higher in Afternoon Trading	31/23/31
Top Midday Gainers	31/23/31
Sector Update: Health Care Stocks Steady Premarket Wednesday	31/23/31
Sector Update: Health Care	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Other languages

Filters